Correction: Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors (Journal of Medicinal Chemistry (2016) 59 (8306-8325) DOI: 10.1021/acs.jmedchem.6b00515);Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors

Journal of Medicinal Chemistry

Volumn 59, Issue 18, 2016, Pages 8306-8325

  Kung, Pei Pei ^a   Rui, Eugene ^a   Bergqvist, Simon ^a   Bingham, Patrick ^a   Braganza, John ^a   Collins, Michael ^a   Cui, Mei ^a   Diehl, Wade ^a   Dinh, Dac ^a   Fan, Connie ^a   Fantin, Valeria R ^a   Gukasyan, Hovhannes J ^a   Hu, Wenyue ^a   Huang, Buwen ^a   Kephart, Susan ^a   Krivacic, Cody ^a   Kumpf, Robert A ^a   Li, Gary ^a   Maegley, Karen A ^a   McAlpine, Indrawan ^a   Nguyen, Lisa ^a   Ninkovic, Sacha ^a   Ornelas, Martha ^a   Ryskin, Michael ^a,b   Scales, Stephanie ^a   Sutton, Scott ^a   Tatlock, John ^a   Verhelle, Dominique ^a   Wang, Fen ^a   Wells, Peter ^a   Wythes, Martin ^a   Yamazaki, Shinji ^a   Yip, Brian ^a   Yu, Xiu ^a   Zehnder, Luke ^a   Zhang, Wei Guo ^a,b   Rollins, Robert A ^a,b   Edwards, Martin ^a   more..

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO N [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 3 ISOPROPOXYBENZAMIDE; 2 CHLORO N [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 3 METHOXYBENZAMIDE; 2 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 7 ISOPROPOXY 3,4 DIHYDROISOQUINOLIN 1 (2H) ONE; 2 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 8 METHYL 7 (PROPAN 2 YLOXY) 3,4 DIHYDROISOQUINOLIN 1 (2H) ONE; 5,8 DICHLORO 2 ( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YLMETHYL) 7 ( 3 METHYL 1H PYRAZOL 4 YL) 3,4 DIHYDRO 2H ISOQUINOLIN 1 ONE; 5,8 DICHLORO 2 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 7 [(TETRAHYDROFURAN 3 YL)OXY] 3,4 DIHYDROISOQUINOLIN 1 (2H) ONE; 6 CHLORO 4 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 7 METHOXY 3,4 DIHYDROBENZO[F][ 1,4 ]OXAZEPIN 5 (2H) ONE; 8 CHLORO 2 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 5 FLUORO 7 [(TETRAHYDROFURAN 3 YL)OXY] 3,4 DIHYDROISOQUINOLIN 1 (2H) ONE; 8 CHLORO 2 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 5 METHYL 7 [(TETRAHYDROFURAN 3 YL)OXY] 3,4 DIHYDROISOQUINOLIN 1 (2H) ONE; 8 CHLORO 2 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 7 ETHOXY 3,4 DIHYDROISOQUINOLIN 1 (2H) ONE; 8 CHLORO 2 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 7 ISOPROPOXY 3,4 DIHYDROISOQUINOLIN 1 (2H) ONE; 8 CHLORO 2 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 7 METHOXY 3,4 DIHYDROISOQUINOLIN 1 (2H) ONE; 8 CHLORO 2 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 7 [(TETRAHYDROFURAN 3 YL)OXY] 3,4 DIHYDROISOQUINOLIN 1 (2H) ONE; 9 CHLORO 2 [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 8 METHOXY 2,3,4,5 TETRAHYDRO 1H BENZO[C]AZEPIN 1 ONE; AMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; ISOQUINOLINE DERIVATIVE; LACTAM DERIVATIVE; LIGAND; N [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 2 FLUORO 3 METHOXYBENZAMIDE; N [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 2 HYDROXY 3 METHOXYBENZAMIDE; N [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 2 METHYLBENZAMIDE; N [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 2,3 DIMETHOXYBENZAMIDE; N [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 3 ISOPROPOXY 2 METHYLBENZAMIDE; N [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 3 METHOXY 2 METHYLBENZAMIDE; N [( 4,6 DIMETHYL 2 OXO 1,2 DIHYDROPYRIDIN 3 YL)METHYL] 3 METHOXYBENZAMIDE; N [( 4,6 DIMETHYL 2 OXO 1,M2 DIHYDROPYRIDIN 3 YL)METHYL] 3 ETHOXY 2 METHYLBENZAMIDE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNINDEXED DRUG; 1,5-DIHYDROISOQUINOLINE; LACTAM; PYRIDONE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; CROSS COUPLING REACTION; CRYSTAL STRUCTURE; CYCLIZATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; DRUG TRANSFORMATION; FEMALE; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; ISOTHERMAL TITRATION CALORIMETRY; LIPOPHILICITY; METABOLIC STABILITY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; MOLECULAR MODEL; NEOPLASM; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLIZATION; DRUG DESIGN; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; FEMALE; HUMANS; ISOQUINOLINES; LACTAMS; MICE; MICE, SCID; MODELS, MOLECULAR; NEOPLASMS; PYRIDONES;

EID: 84988700553     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01747     Document Type: Erratum

References (47)

1. Jones, P. A.; Baylin, S. B. The fundamental role of epigenetic events in cancer Nat. Rev. Genet. 2002, 3, 415-428 10.1038/nrg816
2. Egger, G.; Liang, G.; Aparicio, A.; Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy Nature 2004, 429, 457-463 10.1038/nature02625
3. Chuang, J. C.; Jones, P. A. Epigenetics and microRNAs Pediatr. Res. 2007, 61, 24R-29R 10.1203/pdr.0b013e3180457684
4. Timp, W.; Feinberg, A. P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host Nat. Rev. Cancer 2013, 13, 497-510 10.1038/nrc3486
5. Berdasco, M.; Esteller, M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry Dev. Cell 2010, 19, 698-711 10.1016/j.devcel.2010.10.005
6. Martin, C.; Zhang, Y. The diverse functions of histone lysine methylation Nat. Rev. Mol. Cell Biol. 2005, 6, 838-849 10.1038/nrm1761
7. Ezponda, T.; Licht, J. D. Molecular pathways: deregulation of histone H3 Lysine 27 methylation in cancer-different paths, same destination Clin. Cancer Res. 2014, 20, 5001-5008 10.1158/1078-0432.CCR-13-2499
8. Copeland, R. A.; Solomon, M. E.; Richon, V. M. Protein methyltransferases as a target class for drug discovery Nat. Rev. Drug Discovery 2009, 8, 724-732 10.1038/nrd2974
9. Dawson, M. A.; Kouzarides, T. Cancer epigenetics: from mechanism to therapy Cell 2012, 150, 12-27 10.1016/j.cell.2012.06.013
10. Helin, K.; Dhanak, D. Chromatin proteins and modifications as drug targets Nature 2013, 502, 480-488 10.1038/nature12751
11. Margueron, R.; Reinberg, D. The Polycomb complex PRC2 and its mark in life Nature 2011, 469, 343-349 10.1038/nature09784
12. Bracken, A. P.; Helin, K. Polycomb group proteins: navigators of lineage pathways led astray in cancer Nat. Rev. Cancer 2009, 9, 773-784 10.1038/nrc2736
13. Morin, R. D.; Johnson, N. A.; Severson, T. M.; Mungall, A. J.; An, J.; Goya, R.; Paul, J. E.; Boyle, M.; Woolcock, B. W.; Kuchenbauer, F.; Yap, D.; Humphries, R. K.; Griffith, O. L.; Shah, S.; Zhu, H.; Kimbara, M.; Shashkin, P.; Charlot, J. F.; Tcherpakov, M.; Corbett, R.; Tam, A.; Varhol, R.; Smailus, D.; Moksa, M.; Zhao, Y.; Delaney, A.; Qian, H.; Birol, I.; Schein, J.; Moore, R.; Holt, R.; Horsman, D. E.; Connors, J. M.; Jones, S.; Aparicio, S.; Hirst, M.; Gascoyne, R. D.; Marra, M. A. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nat. Genet. 2010, 42, 181-185 10.1038/ng.518
14. Morin, R. D.; Mendez-Lago, M.; Mungall, A. J.; Goya, R.; Mungall, K. L.; Corbett, R. D.; Johnson, N. A.; Severson, T. M.; Chiu, R.; Field, M.; Jackman, S.; Krzywinski, M.; Scott, D. W.; Trinh, D. L.; Tamura-Wells, J.; Li, S.; Firme, M. R.; Rogic, S.; Griffith, M.; Chan, S.; Yakovenko, O.; Meyer, I. M.; Zhao, E. Y.; Smailus, D.; Moksa, M.; Chittaranjan, S.; Rimsza, L.; Brooks-Wilson, A.; Spinelli, J. J.; Ben-Neriah, S.; Meissner, B.; Woolcock, B.; Boyle, M.; McDonald, H.; Tam, A.; Zhao, Y.; Delaney, A.; Zeng, T.; Tse, K.; Butterfield, Y.; Birol, I.; Holt, R.; Schein, J.; Horsman, D. E.; Moore, R.; Jones, S. J.; Connors, J. M.; Hirst, M.; Gascoyne, R. D.; Marra, M. A. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma Nature 2011, 476, 298-303 10.1038/nature10351
15. McCabe, M. T.; Graves, A. P.; Ganji, G.; Diaz, E.; Halsey, W. S.; Jiang, Y.; Smitheman, K. N.; Ott, H. M.; Pappalardi, M. B.; Allen, K. E.; Chen, S. B.; Della Pietra, A., 3rd; Dul, E.; Hughes, A. M.; Gilbert, S. A.; Thrall, S. H.; Tummino, P. J.; Kruger, R. G.; Brandt, M.; Schwartz, B.; Creasy, C. L. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 2989-2994 10.1073/pnas.1116418109
16. Sneeringer, C. J.; Scott, M. P.; Kuntz, K. W.; Knutson, S. K.; Pollock, R. M.; Richon, V. M.; Copeland, R. A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 20980-20985 10.1073/pnas.1012525107
17. McCabe, M. T.; Ott, H. M.; Ganji, G.; Korenchuk, S.; Thompson, C.; Van Aller, G. S.; Liu, Y.; Graves, A. P.; Della Pietra, A., III; Diaz, E.; LaFrance, L. V.; Mellinger, M.; Duquenne, C.; Tian, X.; Kruger, R. G.; McHugh, C. F.; Brandt, M.; Miller, W. H.; Dhanak, D.; Verma, S. K.; Tummino, P. J.; Creasy, C. L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 2012, 492, 108-112 10.1038/nature11606
18. Knutson, S. K.; Kawano, S.; Minoshima, Y.; Warholic, N. W.; Huang, K.-C.; Xiao, Y.; Kadowaki, T.; Uesugi, M.; Kuznetsov, G.; Kumar, N.; Wigle, T. J.; Klaus, C. R.; Allain, C. J.; Raimondi, A.; Waters, N. J.; Smith, J. J.; Porter-Scott, M.; Chesworth, R.; Moyer, M. P.; Copeland, R. A.; Richon, V. M.; Uenaka, T.; Pollock, R. M.; Kuntz, K. W.; Yokoi, A.; Keilhack, H. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma Mol. Cancer Ther. 2014, 13, 842-854 10.1158/1535-7163.MCT-13-0773
19. Konze, K. D.; Ma, A.; Li, F.; Barsyte-Lovejoy, D.; Parton, T.; Macnevin, C. J.; Liu, F.; Gao, C.; Huang, X. P.; Kuznetsova, E.; Rougie, M.; Jiang, A.; Pattenden, S. G.; Norris, J. L.; James, L. I.; Roth, B. L.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Hahn, K. M.; Wang, G. G.; Vedadi, M.; Jin, J. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1 ACS Chem. Biol. 2013, 8, 1324-1334 10.1021/cb400133j
20. Qi, W.; Chan, H.; Teng, L.; Li, L.; Chuai, S.; Zhang, R.; Zeng, J.; Li, M.; Fan, H.; Lin, Y.; Gu, J.; Ardayfio, O.; Zhang, J. H.; Yan, X.; Fang, J.; Mi, Y.; Zhang, M.; Zhou, T.; Feng, G.; Chen, Z.; Li, G.; Yang, T.; Zhao, K.; Liu, X.; Yu, Z.; Lu, C. X.; Atadja, P.; Li, E. Selective inhibition of EZH2 by a small molecule inhibitor blocks tumor cells proliferation Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 21360-21365 10.1073/pnas.1210371110
21. Gehling, V. S.; Vaswani, R. G.; Nasveschuk, C. G.; Duplessis, M.; Iyer, P.; Balasubramanian, S.; Zhao, F.; Good, A. C.; Campbell, R.; Lee, C.; Dakin, L. A.; Cook, A. S.; Gagnon, A.; Harmange, J. C.; Audia, J. E.; Cummings, R. T.; Normant, E.; Trojer, P.; Albrecht, B. K. Discovery, design, and synthesis of indole-based EZH2 inhibitors Bioorg. Med. Chem. Lett. 2015, 25, 3644-3649 10.1016/j.bmcl.2015.06.056
22. Knutson, S. K.; Warholic, N. M.; Wigle, T. J.; Klaus, C. R.; Allain, C. J.; Raimondi, A.; Porter-Scott, M.; Chesworth, R.; Moyer, M. P.; Copeland, R. A.; Richon, V. M.; Pollock, R. M.; Kuntz, K. W.; Keilhack, H. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 7922-7927 10.1073/pnas.1303800110
23. Wilson, B. G.; Roberts, C. W. SWI/SNF nucleosome remodellers and cancer Nat. Rev. Cancer 2011, 11, 481-492 10.1038/nrc3068
24. Ginn, K. F.; Gajjar, A. Atypical teratoid rhabdoid tumor: current therapy and future directions Front. Oncol. 2012, 2, 114 10.3389/fonc.2012.00114
25. Bitler, B. G.; Aird, K. M.; Garipov, A.; Li, H.; Amatangelo, M.; Kossenkov, A. V.; Schultz, D. C.; Liu, Q.; Shih, I.-M.; Conejo-Garcia, J. R.; Speicher, D. W.; Zhang, R. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers Nat. Med. 2015, 21, 231-238 10.1038/nm.3799
26. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756 10.1021/jm901241e
27. Epizyme press release (corporate update) in October 2015,: http://www.epizyme.com/.
28. Young, R. J. Physical properties in drug design Top. Med. Chem. 2015, 9, 1-68 10.1007/7355-2013-35
29. An independent study of the benzamide carbonyl torsional angle was recently published while we were preparing this article. See: Kuntz, K. W.; Campbell, J. E.; Keilhack, H.; Pollock, R. M.; Knutson, S. K.; Porter-Scott, M.; Richon, V. M.; Sneeringer, C. J.; Wigle, T. J.; Allain, C. J.; Majer, C. R.; Moyer, M. P.; Copeland, R. A.; Chesworth, R. The Importance of Being Me: Magic methyls, methyltransferase inhibitors, and the discovery of Tazemetostat J. Med. Chem. 2016, 59, 1556-1564 10.1021/acs.jmedchem.5b01501
30. Stepan, A. F.; Kauffman, G. W.; Keefer, C. E.; Verhoest, P. R.; Edwards, M. P. Evaluating the differences in cycloalkyl ether metabolism using the design parameter "lipophilic metabolism efficiency" (LipMetE) and a matched molecular pairs analysis J. Med. Chem. 2013, 56, 6985-6990 10.1021/jm4008642
31. Brooun, A.; Gajiwala, K. S.; Deng, Y. L.; Liu, W.; Bolanos, B.; Bingham, P.; He, Y. A.; Diehl, W.; Grable, N.; Kung, P.-P.; Sutton, S.; Maegley, K. A.; Yu, X.; Stewart, A. E. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance Nat. Commun. 2016, 7, 11384 10.1038/ncomms11384
32. Taylor, R.; Kennard, O. Hydrogen-bond geometry in organic crystals Acc. Chem. Res. 1984, 17, 320-326 10.1021/ar00105a004
33. Ladbury, J. E.; Klebe, G.; Freire, E. Adding calorimetric data to decision making in lead discovery: a hot tip Nat. Rev. Drug Discovery 2010, 9, 23-27 10.1038/nrd3054
34. Chaires, J. B. Calorimetry and thermodynamics in drug design Annu. Rev. Biophys. 2008, 37, 135-151 10.1146/annurev.biophys.36.040306.132812
35. Olsson, T. S.; Ladbury, J. E.; Pitt, W. R.; Williams, M. A. Extent of enthalpy-entropy compensation in protein-ligand interactions Protein Sci. 2011, 20, 1607-1618 10.1002/pro.692
36. Snyder, P. W.; Mecinovic, J.; Moustakas, D. T.; Thomas, S. W., 3rd; Harder, M.; Mack, E. T.; Lockett, M. R.; Heroux, A.; Sherman, W.; Whitesides, G. M. Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 17889-17894 10.1073/pnas.1114107108
37. Di, L.; Whitney-Pickett, C.; Umland, J. P.; Zhang, H.; Zhang, X.; Gebhard, D. F.; Lai, Y.; Federico, J. J., 3rd; Davidson, R. E.; Smith, R.; Reyner, E. L.; Lee, C.; Feng, B.; Rotter, C.; Varma, M. V.; Kempshall, S.; Fenner, K.; El-Kattan, A. F.; Liston, T. E.; Troutman, M. D. Development of a new permeability assay using low-efflux MDCKII cells J. Pharm. Sci. 2011, 100, 4974-4985 10.1002/jps.22674
38. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 10.1038/nrd2445
39. Ryckmans, T.; Edwards, M. P.; Horne, V. A.; Correia, A. M.; Owen, D. R.; Thompson, L. R.; Tran, I.; Tutt, M. F.; Young, T. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis Bioorg. Med. Chem. Lett. 2009, 19, 4406-4409 10.1016/j.bmcl.2009.05.062
40. Saal, C.; Petereit, A. C. Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks Eur. J. Pharm. Sci. 2012, 47, 589-595 10.1016/j.ejps.2012.07.019
41. Copeland, R. A.; Basavapathruni, A.; Moyer, M.; Scott, M. P. Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis Anal. Biochem. 2011, 416, 206-210 10.1016/j.ab.2011.05.029
42. Van Aller, G. S.; Pappalardi, M. B.; Ott, H. M.; Diaz, E.; Brandt, M.; Schwartz, B. J.; Miller, W. H.; Dhanak, D.; McCabe, M. T.; Verma, S. K.; Creasy, C. L.; Tummino, P. J.; Kruger, R. G. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2 ACS Chem. Biol. 2014, 9, 622-629 10.1021/cb4008748
43. Beguelin, W.; Popovic, R.; Teater, M.; Jiang, Y.; Bunting, K. L.; Rosen, M.; Shen, H.; Yang, S. N.; Wang, L.; Ezponda, T.; Martinez-Garcia, E.; Zhang, H.; Zheng, Y.; Verma, S. K.; McCabe, M. T.; Ott, H. M.; Van Aller, G. S.; Kruger, R. G.; Liu, Y.; McHugh, C. F.; Scott, D. W.; Chung, Y. R.; Kelleher, N.; Shaknovich, R.; Creasy, C. L.; Gascoyne, R. D.; Wong, K. K.; Cerchietti, L.; Levine, R. L.; Abdel-Wahab, O.; Licht, J. D.; Elemento, O.; Melnick, A. M. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation Cancer Cell 2013, 23, 677-692 10.1016/j.ccr.2013.04.011
44. Edwards, M. P.; Kumpf, R. A.; Kung, P.-P.; McAlpine, I. J.; Ninkovic, S.; Rui, E. Y.; Sutton, S. C.; Tatlock, J. H.; Wythes, M. J.; Zehnder, L. R. Aryl and heteroaryl fused lactams. WO 2014/097041 A1, June 26, 2014.
45. Ghosh, A. K.; Thompson, W. J.; Holloway, M. K.; McKee, S. P.; Duong, T. T.; Lee, H. Y.; Munson, P. M.; Smith, A. M.; Wai, J. M.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Huff, J. R.; Anderson, P. S. Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands J. Med. Chem. 1993, 36, 2300-2310 10.1021/jm00068a006
46. Khurana, J. M.; Kukreja, G. Rapid reduction of nitriles to primary amines with nickel boride at ambient temperature Synth. Commun. 2002, 32, 1265-1269 10.1081/SCC-120003619
47. Kurouchi, H.; Sumita, A.; Otani, Y.; Ohwada, T. Protonation switching to the least-basic heteroatom of carbamate through cationic hydrogen bonding promotes the formation of isocyanate cations Chem.-Eur. J. 2014, 20, 8682-8690 10.1002/chem.201402447